ATE252602T1 - Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen - Google Patents

Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen

Info

Publication number
ATE252602T1
ATE252602T1 AT97941371T AT97941371T ATE252602T1 AT E252602 T1 ATE252602 T1 AT E252602T1 AT 97941371 T AT97941371 T AT 97941371T AT 97941371 T AT97941371 T AT 97941371T AT E252602 T1 ATE252602 T1 AT E252602T1
Authority
AT
Austria
Prior art keywords
menb
vaccine compositions
mimetics
antibodies
meningococcus
Prior art date
Application number
AT97941371T
Other languages
English (en)
Inventor
Dan Granoff
Gregory R Moe
Original Assignee
Chiron Corp
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Childrens Hosp Medical Center filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE252602T1 publication Critical patent/ATE252602T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97941371T 1996-08-27 1997-08-27 Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen ATE252602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2579996P 1996-08-27 1996-08-27
PCT/US1997/015167 WO1998008874A1 (en) 1996-08-27 1997-08-27 Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions

Publications (1)

Publication Number Publication Date
ATE252602T1 true ATE252602T1 (de) 2003-11-15

Family

ID=21828119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97941371T ATE252602T1 (de) 1996-08-27 1997-08-27 Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen

Country Status (7)

Country Link
US (4) US6048527A (de)
EP (1) EP0922059B1 (de)
JP (2) JP4150082B2 (de)
AT (1) ATE252602T1 (de)
CA (1) CA2264585C (de)
DE (1) DE69725739T2 (de)
WO (1) WO1998008874A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
JP4150082B2 (ja) * 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
EP0939647B2 (de) 1996-08-27 2006-07-12 Chiron Corporation Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
EP1007546B1 (de) 1997-08-27 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Molekular-mimetika von meningokokkus b epitopen
GB9823835D0 (en) * 1998-10-30 1998-12-23 Univ London Component for vaccine
AU760257B2 (en) * 1998-12-14 2003-05-08 Palatin Technologies, Inc. Metallopeptide combinatorial libraries and applications
ES2184659T1 (es) 1999-08-06 2003-04-16 Ivigene Corp Polinucleotidos microbianos expresados durante la infeccion de un organismo hospedante.
US7033748B2 (en) * 1999-08-06 2006-04-25 Ivigene Corporation Identification of microbial polynucleotides expressed during infection of a host
US7049398B1 (en) * 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
US7189405B1 (en) * 1999-10-29 2007-03-13 Rice Peter A Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
AU1623801A (en) * 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
CN102172398A (zh) * 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7385025B2 (en) * 2000-12-19 2008-06-10 Palatin Technologies, Inc. Metallopeptide compounds
AU2002238106A1 (en) * 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US20020131953A1 (en) * 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
US7534444B2 (en) * 2001-04-17 2009-05-19 Novattis Vaccines And Diagnostics, Inc. Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003089473A1 (en) * 2002-04-19 2003-10-30 Yonsei University Vaccine composition for preventing meningococcal disease
EP1411061A1 (de) * 2002-10-16 2004-04-21 Centre National De La Recherche Scientifique (Cnrs) Poly-alpha2,8-sialylsäure mimetische Peptide und ihre Verwendungen
BRPI0411815A (pt) * 2003-06-23 2006-08-08 Baxter Int vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
AR048840A1 (es) * 2004-05-11 2006-05-31 Boehringer Ingelheim Int Epitopes inductores de la muerte de las celulas t
JP2008509886A (ja) * 2004-06-23 2008-04-03 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 多糖誘導体および免疫応答の誘導における用途
US8148335B2 (en) * 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
WO2007075921A2 (en) 2005-12-23 2007-07-05 Children's Hospital & Research Center At Oakland De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
AR058736A1 (es) * 2005-12-29 2008-02-20 Ct Ingenieria Genetica Biotech Peptidos mimeticos de carbohidratos y su empleo en formulaciones farmaceuticas
WO2007084856A2 (en) * 2006-01-13 2007-07-26 Baxter International Inc. Method for purifying polysaccharides
GB0606155D0 (en) * 2006-03-28 2006-05-10 Liverpool School Of Tropical M Bacterial vaccine
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20100189740A1 (en) * 2007-06-20 2010-07-29 Francis Michon Modified polysaccharides for conjugate vaccines
EP2183261A4 (de) * 2007-07-03 2010-09-15 Childrens Hosp & Res Ct Oak Polysialylsäurederivate, herstellungsverfahren und anwendungen bei der steigerung von produktion und targeting von krebsantigenen
EP2173759A4 (de) * 2007-07-03 2014-01-29 Childrens Hosp & Res Ct Oak Oligosialinsäúrederivate, verfahren zu ihrer herstellung und ihre immunologische verwendung
EP2173166A4 (de) * 2007-07-03 2010-08-11 Childrens Hosp & Res Ct Oak Polysialinsäure-de-n-acetylase-hemmer und verfahren zu ihrer verwendung
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090156459A1 (en) * 2007-11-16 2009-06-18 Pharmain Corporation Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009117409A2 (en) * 2008-03-18 2009-09-24 Merck & Co., Inc. A high throughput protein interaction assay
AR077636A1 (es) * 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
US8829426B2 (en) 2011-07-14 2014-09-09 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
EP2823312B1 (de) * 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro-wirksamkeits basierte assay für protein-basierten meningokokken-impfstoffe
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
US9770504B2 (en) * 2013-05-03 2017-09-26 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
EP4153999A1 (de) * 2020-05-19 2023-03-29 Laboratory Corporation of America Holdings Verfahren und systeme zum quantitativen nachweis von antikörpern

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPH0720878B2 (ja) * 1983-11-21 1995-03-08 ザ ウエルカム フアウンデ−シヨン リミテツド 改善された複合体、それらの製造法および該複合体を含有する製剤
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
ATE120093T1 (de) * 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
HU9201966D0 (en) * 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
EP0939647B2 (de) 1996-08-27 2006-07-12 Chiron Corporation Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
EP1007546B1 (de) 1997-08-27 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Molekular-mimetika von meningokokkus b epitopen

Also Published As

Publication number Publication date
US6642354B2 (en) 2003-11-04
WO1998008874A1 (en) 1998-03-05
US7063949B2 (en) 2006-06-20
CA2264585A1 (en) 1998-03-05
DE69725739D1 (de) 2003-12-11
US20020197260A1 (en) 2002-12-26
JP2001500372A (ja) 2001-01-16
US20060035284A1 (en) 2006-02-16
CA2264585C (en) 2005-06-14
JP4150082B2 (ja) 2008-09-17
EP0922059A1 (de) 1999-06-16
US7504254B2 (en) 2009-03-17
EP0922059B1 (de) 2003-10-22
US6048527A (en) 2000-04-11
JP2008044947A (ja) 2008-02-28
US20040077840A1 (en) 2004-04-22
DE69725739T2 (de) 2004-08-05

Similar Documents

Publication Publication Date Title
ATE252602T1 (de) Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
EP1630168A3 (de) Molekular-mimetika von meningokokkalen B Epitopen
AR245778A1 (es) Secuencia de nucleotido que codifica una proteina de membrana exterior de neisseria meningitis y uso de dicha proteina en preparaciones de vacuna
LU92488I2 (fr) Dimethyl fumarate
Densen Complement deficiencies and meningococcal disease
DK0680512T3 (da) Immunogent meningokok LPS og ydermembranvesikler og vaccine deraf
EP2270046A3 (de) Verfahren und Zusammensetzungen zur Behandlung von mit Hämolyse assoziierten Krankheiten
HU9402167D0 (en) Monomeric and dimeric antibody-fragment fusion proteins
ATE240395T1 (de) Antikörper gegen e-selektin
BR9814276A (pt) Antìgenos de superfìcie
CA2439428A1 (en) Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
DE69000641D1 (de) Imipramin enthaltende arzneizubereitungen.
PT929669E (pt) Antigenios derivados das filagrinas e a sua utilizacao para o diagostico da poliartrite reumatoide
SE9402880D0 (sv) New peptide derivatives
DE69232975D1 (de) Protein p100von menschlichem Herpesvirus Typ 6, die korrespondierenden DNS Squenzen, ihre Herstellung und Verwendung
Ellison et al. Serologic measures in the prevention of periodontal disease
NO912823D0 (no) Fremgangsmaate for fremstilling av klasse ii-proteinet av neisseria meningitidis samt vaksiner som inneholder dette.
DE59805440D1 (de) Verwendung von lbp zur sepsistherapie
Harris ISOLATION AND CHARACTERIZATION OF LOW MOLECULAR WEIGHT, NON-AGGREGATED ANTIHEMOPHILIC FACTOR FROM FRESH HUMAN PLASMA.
SORVILLO THE INTERACTION OF HUMAN FIBRONECTIN WITH SUBCOMPONENT CIQ OF THE COMPLEMENT SYSTEM
TR199900160T2 (xx) Immunoterapötik aktif maddeler olarak kullanışlı polipeptidler.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0922059

Country of ref document: EP

EEFA Change of the company name